Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial

Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial

Sirolimus (SRL) has been reported to benefit patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). This study aimed to compare SRL with tacrolimus (TAC) in living-donor LT (LDLT) recipients beyond the Milan criteria. This study was initially designed to enrol 45 recipien...

Full description

Bibliographic Details
Main Authors: Kwang-Woong Lee, Seong Hoon Kim, Kyung Chul Yoon, Jeong-Moo Lee, Jae-Hyung Cho, Suk Kyun Hong, Nam-Joon Yi, Sung-Sik Han, Sang-Jae Park, Kyung-Suk Suh
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Journal of Clinical Medicine
Subjects:
sirolimus
hepatocellular carcinoma
transplantation
survival
Online Access:https://www.mdpi.com/2077-0383/9/10/3264

Internet

https://www.mdpi.com/2077-0383/9/10/3264

Similar Items